Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 7/20 | 0.52 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.47 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.47 |
| ▸ | RORC | P51449 | 2/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.45 |
| ▸ | RBP4 | P02753 | 1/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | P4HB | P07237 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL536257 | 0.86 | NOTUM (0.55) | NOTUMPDK2RBP4ALDH1A1AKR1C3 | |
| SCHEMBL2776641 | 0.85 | NOTUM (0.54) | NOTUMPDK2RBP4ALDH1A1AKR1C3 | |
| SCHEMBL6255106 | 0.84 | PDK2 (0.50) | PDK2ALDH1A1AKR1C3AKR1C2SMN1; SMN2 | |
| SCHEMBL10035005 | 0.84 | NOTUM (0.52) | NOTUMPDK2RBP4ALDH1A1AKR1C3 | |
| SCHEMBL410088 | 0.83 | RORC (0.52) | PDK2RORCALDH1A1AKR1C3AKR1C2 | |
| SCHEMBL28144725 | 0.81 | NOTUM (0.67) | NOTUMPDK2PDK1PDK3PDK4 | |
| SCHEMBL10907300 | 0.81 | NOTUM (0.66) | NOTUMPDK2PDK1PDK3PDK4 | |
| SCHEMBL10035257 | 0.81 | NOTUM (0.52) | NOTUMPDK2MRGPRX4RBP4AKR1C3 | |
| SCHEMBL13011190 | 0.81 | VCAM1 (0.51) | NOTUMPDK2ALDH1A1SMN1; SMN2 | |
| SCHEMBL536245 | 0.81 | TRPA1 (0.49) | NOTUMPDK2MRGPRX4RBP4AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414342-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-05-31 | — | — | EP | disclosed |
| CN-102803238-B | Oxadiazole Derivatives | MERCK SERONO S.A. (CH) | 2015-09-30 | — | — | CN | disclosed |
| US-8802704-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2014-08-12 | — | — | US | disclosed |
| US-20120035226-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-02-09 | — | — | US | disclosed |
| EP-2414342-A1 | OXADIAZOLE DERIVATIVES | Merck Serono S.A. (CH) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010112461-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035226-A1 | OXADIAZOLE DERIVATIVES | OXA1L, HLA-DRB1, SSB | NOTUM 3234/4885PDK2 404/4885PDK1 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.